Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma

Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma Full article

Journal

Bulletin of Experimental Biology and Medicine
ISSN: 0007-4888

Output data

Year: 2019, Volume: 166, Number: 5, Pages: 661-666 Pages count : DOI: 10.1007/s10517-019-04413-3

Tags

Lewis lung carcinoma; metastases; topotecan; tyrosyl-DNA phosphodiesterase-1 inhibitor; morphometry

Authors

Koldysheva E. V. ¹ , Men'shchikova A. P. ⁵ , Lushnikova E. L. ¹ , Popova N. A. ^2,5 , Kaledin V. I. ² , Nikolin V. P. ² , Zakharenko A. L. ³ , Luzina O. A. ⁴ , Salakhutdinov N. F. ^4,5 , Lavrik O. I. ^3,5

Affiliations

1	(Данные Web of science) Fed Res Ctr Fundamental & Translat Med, Inst Mol Pathol & Pathomorphol, Novosibirsk, Russia
2	(Данные Web of science) Russian Acad Sci, Siberian Div, Fed Res Ctr Inst Cytol & Genet, Novosibirsk, Russia
3	(Данные Web of science) Russian Acad Sci, Siberian Div, Inst Chem Biol & Fundamental Med, Novosibirsk, Russia
4	(Данные Web of science) Russian Acad Sci, Siberian Div, NN Vorozhtsov Novosibirsk Inst Organ Chem, Novosibirsk, Russia
5	(Данные Web of science) Novosibirsk Natl Res State Univ, Novosibirsk, Russia

The antimetastatic activity of combined or individual administration of topotecan and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibitor was examined under various administration schedules in mice with Lewis lung carcinoma modeled by intravenous injection of 200,000 clone/mouse. The greatest antimetastatic effect was observed after combined use of topotecan and Tdp1 inhibitor as documented by macroscopic study of the lungs that revealed the decreased metastatic scores by 76, 91, or 74% at the respective inhibitor doses of 2, 4, or 6 mg/mouse, respectively, in parallel with inhibition of metastasis up to 98% (at inhibitor dose of 4 mg/mouse) and morphological and morphometric analyses of the lung sections, which revealed elevation of metastasis growth delay index to 86 and 63% at the respective inhibitor doses of 4 and 6 mg/mouse, respectively. The combined administration of topotecan and Tdp1 inhibitor is viewed as the most effective way to eliminate the metastatic formations with possible restitution of focal lesions.

Koldysheva E.V. , Men'shchikova A.P. , Lushnikova E.L. , Popova N.A. , Kaledin V.I. , Nikolin V.P. , Zakharenko A.L. , Luzina O.A. , Salakhutdinov N.F. , Lavrik O.I.
Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma
Bulletin of Experimental Biology and Medicine. 2019. V.166. N5. P.661-666. DOI: 10.1007/s10517-019-04413-3 WOS Scopus РИНЦ

Колдышева Е.В. , Меньщикова А.П. , Лушникова Е.Л. , Попова Н.А. , Каледин В.И. , Николин В.П. , Захаренко А.Л. , Лузина О.А. , Салахутдинов Н.Ф. , Лаврик О.И.
Антиметастатическая активность комбинации топотекана и ингибитора тирозил-днк-фосфодиэстеразы 1 на модели карциномы легкого Льюис
Бюллетень экспериментальной биологии и медицины (B EXP BIOL MED+). 2018. Т.166. №11. С.609-615. РИНЦ

Published print:	Mar 1, 2019
Published online:	Mar 22, 2019

Web of science	WOS:000463162900016
Scopus	2-s2.0-85063660758
Elibrary	38719263
OpenAlex	W2923229634